These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21152943)

  • 1. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Hagihara H; Nouso K; Kobayashi Y; Iwasaki Y; Nakamura S; Kuwaki K; Toshimori J; Miyatake H; Ohnishi H; Shiraha H; Yamamoto K
    Int J Clin Oncol; 2011 Jun; 16(3):210-20. PubMed ID: 21152943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
    Lee D; Chung YH; Kim JA; Park WH; Jin YJ; Shim JH; Ryu SH; Jang MK; Yu E; Lee YJ
    Cancer; 2013 Jun; 119(12):2239-46. PubMed ID: 23564564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.
    Tanimoto Y; Tashiro H; Aikata H; Amano H; Oshita A; Kobayashi T; Kuroda S; Tazawa H; Takahashi S; Itamoto T; Chayama K; Ohdan H
    Ann Surg Oncol; 2012 Feb; 19(2):418-25. PubMed ID: 21710324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
    Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Saito T; Chiba T; Suzuki E; Shinozaki M; Goto N; Kanogawa N; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Kanda T; Miyazaki M; Yokosuka O
    Int J Med Sci; 2014; 11(7):707-12. PubMed ID: 24843320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
    Jeong SC; Aikata H; Katamura Y; Azakami T; Kawaoka T; Saneto H; Uka K; Mori N; Takaki S; Kodama H; Waki K; Imamura M; Shirakawa H; Kawakami Y; Takahashi S; Chayama K
    World J Gastroenterol; 2007 Oct; 13(40):5343-50. PubMed ID: 17879404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Shinkawa H; Hasegawa K; Arita J; Akamatsu N; Kaneko J; Sakamoto Y; Kokudo N
    Ann Surg Oncol; 2017 Oct; 24(11):3196-3202. PubMed ID: 28707053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
    Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
    Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
    Lee SH; Jin YJ; Shin JY; Lee JW
    Medicine (Baltimore); 2017 Jan; 96(1):e5321. PubMed ID: 28072684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
    Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    Ann Surg Oncol; 2019 Dec; 26(13):4566-4575. PubMed ID: 31602577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
    Miyatake H; Kobayashi Y; Iwasaki Y; Nakamura S; Ohnishi H; Kuwaki K; Toshimori J; Hagihara H; Nouso K; Yamamoto K
    Dig Dis Sci; 2012 Apr; 57(4):1092-101. PubMed ID: 21989822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.